关注
Neus Pagès-Puigdemont
Neus Pagès-Puigdemont
PharmD, PhD. Clinical Pharmacist. Hospital de la Santa Creu i Sant Pau (Barcelona)
在 santpau.cat 的电子邮件经过验证
标题
引用次数
引用次数
年份
Métodos para medir la adherencia terapeútica
N Pagès-Puigdemont, MI Valverde-Merino
Ars Pharmaceutica (Internet) 59 (3), 163-172, 2018
3382018
Adherencia terapéutica: factores modificadores y estrategias de mejora
MI Valverde-Merino
Ars Pharmaceutica (Internet) 59 (4), 251-258, 2018
1802018
Patients’ perspective of medication adherence in chronic conditions: a qualitative study
N Pages-Puigdemont, MA Mangues, M Masip, G Gabriele, ...
Advances in therapy 33, 1740-1754, 2016
1442016
Methods to assess medication adherence
N Pagès-Puigdemont, M Isabel Valverde-Merino
Ars Pharmaceutica 59 (3), 163-172, 2018
472018
Determinants of medication adherence among chronic patients from an urban area: a cross-sectional study
N Pages-Puigdemont, L Tuneu, M Masip, P Valls, T Puig, MA Mangues
European Journal of Public Health 29 (3), 419-424, 2019
222019
Standard headache and neuralgia treatments and SARS-CoV-2: opinion of the Spanish Society of Neurology’s Headache Study Group
N Morollón, R Belvís, A De Dios, N Pagès, C González-Oria, G Latorre, ...
Neurología (English Edition) 35 (9), 628-632, 2020
162020
Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment
M Masip, L Tuneu, N Pagès, X Torras, A Gallego, JM Guardiola, MJ Faus, ...
International journal of clinical pharmacy 37, 1143-1151, 2015
162015
A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence
D Medina-Catalán, P Riera, N Pagès-Puigdemont, M Masip, ...
International Journal of Clinical Pharmacy 44 (3), 725-730, 2022
72022
Medication adherence: modifiers and improvement strategies
N Pages-Puigdemont, M Isabel Valverde-Merino
Ars Pharmaceutica 59 (4), 251-258, 2018
72018
Potential drug–drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir±DASABUVIR±ribavirin in clinical practice
E González‐Colominas, MC Londoño, RM Morillas, X Torras, S Mojal, ...
Journal of Gastroenterology and Hepatology 33 (5), 1100-1107, 2018
62018
Abordaje cualitavio y cuantitativo de la adherencia a los tratamientos farmacológicos
MA Mangues Bafalluy, L Tuneu Valls
Universidad de Granada, 2017
52017
Efectividad del tratamiento de la hepatitis C en pacientes atendidos en la consulta de atención farmacéutica
JM Sotoca-Momblona, M Rodriguez-Reyes, C Bartres-Viñas, ...
Ars Pharmaceutica (Internet) 61 (1), 45-47, 2020
42020
AB0402 THERAPEUTIC ADHERENCE AND PERSISTENCE OF TOFACITINIB AND BARICITINIB IN RHEUMATOID ARTHRITIS PATIENTS IN DAILY CLINICAL PRACTICE.
H Codes-Mendez, C Martinez-Molina, M Masip, P Riera, NP Puigdemont, ...
Annals of the Rheumatic Diseases 81 (Suppl 1), 1330-1330, 2022
32022
¿ Cuál es el beneficio del uso de las estatinas en el anciano
CM Cantera, S Creu, S Pau, JT Borrell
Butlletí d’Informació Terapèutica 25 (6), 2014
32014
Tratamientos habituales utilizados en cefaleas, neuralgias y SARS-CoV-2. Posicionamiento del grupo de estudio de cefaleas de la Sociedad Española de Neurología
N Morollón, R Belvís, A De Dios, N Pagès, C González-Oria, G Latorre, ...
Neurología 35 (9), 628-632, 2020
22020
Design of a relative value unit-based tool for the measurement and reimbursement of pharmacy services for clinical trials
N Pagès-Puigdemont, G Molas, MQ Gorgas, N Berga, C Codina, M Cruel, ...
European Journal of Hospital Pharmacy 26 (4), 205-209, 2019
22019
4CPS-251 Impact of a multidisciplinary team in reducing polypharmacy and treatment complexity in home care patients
N Pagès-Puigdemont, M Rovira-Illamola, L Gené, I Garrell, L GUerrero, ...
European Journal of Hospital Pharmacy 26 (Suppl 1), A186-A186, 2019
22019
What if a monoclonal antibody doesn't work as a migraine preventive treatment? Description of the experience in switching between monoclonals antibodies in a Headache Unit
N Morollon, R Belvis, A De Dios, N Pages, M Massip
JOURNAL OF HEADACHE AND PAIN 22 (SUPPL 1), 106-106, 2021
12021
Changes in antiretroviral treatment due to interactions in co-infected patients who initiate treatment for chronic hepatitis C virus
M Saavedra Mitjans, N Pages Puigdemont, N Garin Escriva, ...
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY 39 (1), 214-215, 2017
12017
Treatment with Sofosbuvir+ Simeprevir for 12 Weeks in HCV Compensated Cirrhosis (Genotypes 1 and 4); The Use of Ribavirin Does Not Influence Sustained Viral Response
A Gallego, E Alvarado, C Gely, N Pagès, M Masip, N Margall, X Torras, ...
Journal of Hepatology 2 (64), S741-S742, 2016
12016
系统目前无法执行此操作,请稍后再试。
文章 1–20